Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: CT-2103 (Xyotax)
Sponsor: Dana-Farber Cancer Institute
Collaborators: Beth Israel Deaconess Medical Center|Brigham and Women's Hospital